Photo Credit: J Am Coll Cardiol. Central Illustration (adapted). High-risk, nonstenotic intracranial plaque appears to be a more important cause of embolic stroke of undetermined source (ESUS) than ...
Please provide your email address to receive an email when new articles are posted on . BOSTON — In PROTECTED TAVR, the largest-ever randomized trial of transcatheter aortic valve replacement, ...
A series of neutral trials on anticoagulation in embolic stroke of undetermined source (ESUS) has moved the needle scientifically but left physicians with questions about secondary prevention and the ...
CHICAGO, IL—Cerebral embolic protection devices are infrequently used during transcatheter aortic valve implantation procedures in the United States, and new data suggest their use does not appear to ...
For patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack, asundexian, a factor XIa inhibitor ...
CHICAGO -- Routine use of devices to prevent cerebral emboli during transcatheter aortic valve implantation (TAVI) did not prevent strokes, a large randomized trial showed. Incidence of stroke within ...
United States Embolic Protection Device Market is expected to reach US$ 650 million by 2033 from US$ 360 million in 2024, with a CAGR of 6.96% from 2025 to 2033. Rising cardiovascular operations, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results